Best practices as recommended by WHO and United States Pharmacopoeia are being implemented for performing tests on therapeutic goods.
Recent Updates
- SRO 620(I)/2023: Fixation of Maximum Retail Price of Cardiac Stents May 22, 2023
- SRO 595(I)/2023: Maximum Retail Price of Drugs and Biologicals Under CPI. May 22, 2023
- Decisions of 57th Meeting of Medical Device Board (Deficiency letter for Medical Devices Applications) May 18, 2023
- Recall Alert: Medical Devices; Aquavent Neonatal Breathing Circuits by M/s. Armstrong Medical Limited, Ireland May 18, 2023
- Minutes of 326th meeting of Registration Board held from 14th to 16th March, 2023 May 13, 2023
- DRAP invites Comments on Draft Guidance Document for Submission of Application on Form 5F (CTD) for Registration of Biological Drug Products for Human Use May 9, 2023
- Rapid Alert: Falsified Sildenafil Citrate 100mg Tablets identified in the market May 8, 2023
- Stakeholders’ Comments are invited on the Draft Guidelines on Patient Information Leaflet May 5, 2023
- Minutes of the meetings of Clinical Studies Committee (CSC) conducted in the light of Bio Study Rules 2017 May 5, 2023
- DRAP issued a Draft of Guidelines on the Lot Release of Biological Drugs May 5, 2023
Leadership
- Dr. M. Fakhr-e-Alam
Secretary, Ministry of NHSR&C - Mr. Asim Rauf
Chief Executive Officer, DRAP

E-Services
With the effective use of Information Technology, we have implemented a number of online services and continually working for more. Click Here to Register an account for following online services. Online Challan & Fee Submission fee.dra.gov.pk Commercial Import & Export

Guidelines
Regulatory compliance is essential and indispensable in order to assure the safety, quality and efficacy of therapeutic goods. Guidance documents published by the Authority are meant to explain the current interpretation or policy for better understanding of the industry and

Quality Control Labs
For ensuring quality therapeutic goods, a network of quality control laboratories has been established. DRAP approved products and suspect therapeutic goods are tested for their quality in accordance with best international practices. To keep the citizens safe from substandard and

Therapeutic Products Recalls
The Recalled Product Index provides access to consumers, healthcare professionals, industry, hospitals and sale outlets related to the information of recalled action taken for defective therapeutic goods. The following section provides an index of recalled actions in which a public

Health Professional Alerts
DRAP’s issues safety updates and alerts related to the therapeutic goods in order to ensure that healthcare professionals and other stakeholders have timely access to the relevant information on safety, quality and efficacy issues or benefit/risk evaluations of the drugs,

Open Consultations
Public consultation enables organizations to consider views and ideas from the citizens and relevant stakeholders during the development of new regulatory mechanisms, either through the enactment of new rules and policies or changes to existing ones or by the development
Implementation of Online Import & Export System
We are delighted to announce that DRAP has taken one more facilitation step for the convenience of Importers and Exporters.
Do you know?
DRAP ensures that every drug, medical device or cosmetic, alternative medicine and health product must have a certain standard of quality and is safe and effective for your use. See in links below how it is done and what to do in case you find a suspect therapeutic good.